<?xml version="1.0" encoding="UTF-8"?>
<p id="Par17">Of the 51 participants who enrolled in the study by Edelman et al., 2019, only 23 participants remained in the study for up to 24 weeks [
 <xref ref-type="bibr" rid="CR45">45</xref>]. 82% of Cook et al., 2017 study participants completed the course of treatment [
 <xref ref-type="bibr" rid="CR44">44</xref>]. Among 51 people with HIV/AUD enrolled in the study by Korthuis. et al., 2017, 83% of XR-NTX and 50% of treatment as usual (TAU) pharmacotherapy groups were retained on the treatment within 16 weeks [
 <xref ref-type="bibr" rid="CR47">47</xref>]. Springer et al., 2018 studied the effects of XR-NTX on 100 (2:1 randomization) incarcerated individuals with HIV/AUD and reported no significant difference between treatment retention for both XR-NTX and placebo groups after 6 months [
 <xref ref-type="bibr" rid="CR48">48</xref>].
</p>
